BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Pharma, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $502.08M | $221.90M | $9.30M | – | – | – | – | 100.0% | +126.3% |
| Reportable Segment | – | $221.90M | $9.30M | $77.65M | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | YoY |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$523.41M | -$592.97M | -$607.37M | – | – | – | – | -11.7% |
| Reportable Segment | – | -$592.97M | -$607.37M | -$512.20M | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $362.37M | $2.88M | $0 | $1.55M | $3.79M | $0 | – | 72.2% | +12464.8% |
| License and services revenue | $128.32M | $218.85M | $9.30M | $76.09M | $65.92M | $8.25M | – | 25.6% | -41.4% |
| Royalty revenue | $11.39M | $169.00K | $0 | – | – | – | – | 2.3% | +6637.3% |
| License | – | – | – | – | $65.92M | $8.25M | $40.56M | – | – |
By region
From the segment and revenue-disaggregation notes of BridgeBio Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.